Company data sheet · Novartis
Novartis: profitable every year.
- Industry
- Pharmaceutical Preparations Manufacturing
- Headquarters
- Switzerland
- Ticker
- NVS (NYSE)
- Sources
- SEC filings (2001–2026), Stratrix's verified Decision Cases, market data and official economic statistics for Switzerland
- Data as of
- November 1, 2026
- Four decisions on record. Stratrix has verified four of Novartis's big decisions, each with what happened next. The hardest year after: "Novartis Spent a Decade Selling Off Its Own Insurance Policy. The Bet Is Now Naked", with its shares 31 points behind the S&P 500 over the next three years.
- Profitable every year. Novartis made money in each of its last ten fiscal years, from $6.7 billion (2016) to $24 billion (2021).
Financial results
| Fiscal year | Revenue | Net income |
|---|
As reported in its annual filings. Losses in red.
Stratrix Decision Cases
- 2023Novartis Spent a Decade Selling Off Its Own Insurance Policy. The Bet Is Now Naked.
- 2019Novartis Priced Zolgensma at $2.125M With a Watchdog's Blessing — Then Sat on Manipulated Data
- 2018Novartis Paid $8.7 Billion to Cure a Disease Once. The Hard Part Is Doing It Twice.
- 2015Novartis Sold Off Its Adjacencies One by One — The Only Bet That Paid Was a Molecule
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Economic context: 6 measures for Switzerland, every year since 2016, from the official sources.
- Peer comparison: against 264 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.